BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will ...

The study of immuno-metabolism explores how metabolic processes influence the immune system, particularly via antigen presentation. Recent findings reveal ...

Antibiotic-resistant bacteria are a serious public health threat. Understanding the biology of these bacteria—such as how ...

The Goldman Sachs Group upgraded shares of Adaptive Biotechnologies (NASDAQ:ADPT – Free Report) from a neutral rating to a buy rating in a research report released on Friday, Marketbeat.com reports.

Fintel reports that on March 21, 2025, Goldman Sachs upgraded their outlook for Adaptive Biotechnologies (NasdaqGS:ADPT) from Neutral to Buy. Analyst Price Forecast Suggests 27.23% Upside As of March ...

Phage therapy has recently garnered significant attention as an alternative or adjunctive approach to conventional antibiotic treatments, especially against ...

Antibodies, which recognize viruses and proteins that the body has encountered before, have long gotten most of the credit ...

Our immune system works to fight infections immediately, but also maintain long-term immunity. Two waves of protection help neutralize and eliminate diseas | Immunology ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...